Fosbretabulin Disodium

TargetMol
Product Code: TAR-T6272
Supplier: TargetMol
CodeSizePrice
TAR-T6272-1mg1mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-2mg2mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-5mg5mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-25mg25mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-50mg50mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6272-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium, a water-soluble prodrug of Combretastatin A4 (CA4), is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM). Fosbretabulin Disodium inhibits the polymerization of tubulin (IC50: 2.4 μM), and also disrupts tumor vasculature.
CAS:
168555-66-6
Formula:
C18H19Na2O8P
Molecular Weight:
440.295
Pathway:
Cytoskeletal Signaling; Apoptosis
Purity:
0.9996
SMILES:
[Na+].[Na+].COc1ccc(C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP([O-])([O-])=O
Target:
Apoptosis; Microtubule Associated

References

Tozer GM, et al. Cancer Res, 1999, 59(7), 1626-1634. Han T, Duan Q, Yang R, et al. Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI. Diagnostic and Interventional Radiology. 2021, 27(5): 587. Kathou C, et al. Blood, 2002, 99(6), 2060-2069. Dark GG, et al. Cancer Res 1997, 57(10), 1829-1834. Meng F, Zou B, Yang R, et al. The diagnostic efficiency of the perfusion-related parameters in assessing the vascular disrupting agent (CA4P) response in a rabbit VX2 liver tumor model. Acta Radiologica. 2021: 02841851211032450. Vincent L, et al. J Clin Invest, 2005, 115(11), 21992-32006. Woods JA, et al. Br J Cancer 1995, 71(4), 705-711.